Journal
JOURNAL OF MOLECULAR BIOLOGY
Volume 432, Issue 7, Pages 2080-2098Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jmb.2020.01.033
Keywords
biochemistry; protein aggregation; small molecules; NMR WaterLOGSY; mass spectrometry
Categories
Funding
- GO-Bio initiative of the German Federal Ministry for Education and Research (BMBF) [BMBF 0313881]
- ERA-NET NEURON initiative ABETA ID of the BMBF [BMBF 01W1301]
- Berlin Institute of Health (BIH) [CRG 1.1.2.a.3]
- Helmholtz Validation Fund of the Helmholtz Association [HVF-0013]
- Stiftung Charite/Private Excellence Initiative Johanna Quandt, Germany
Ask authors/readers for more resources
The self-assembly of the 42-residue amyloid-beta peptide, A beta 42, into fibrillar aggregates is associated with neuronal dysfunction and toxicity in Alzheimer's disease (AD) patient brains, suggesting that small molecules acting on this process might interfere with pathogenesis. Here, we present experimental evidence that the small molecule sclerotiorin (SCL), a natural product belonging to the group of azaphilones, potently delays both seeded and nonseeded A beta 42 polymerization in cell-free assays. Mechanistic biochemical studies revealed that the inhibitory effect of SCL on fibrillogenesis is caused by its ability to kinetically stabilize small A beta 42 oligomers. These structures exhibit low beta-sheet content and do not possess seeding activity, indicating that SCL acts very early in the amyloid formation cascade before the assembly of seeding-competent, beta-sheet-rich fibrillar aggregates. Investigations with NMR WaterLOGSY experiments confirmed the association of A beta 42 assemblies with SCL in solution. Furthermore, using ion mobility-mass spectrometry, we observed that SCL directly interacts with a small fraction of A beta 42 monomers in the gas phase. In comparison to typical amyloid fibrils, small SCL-stabilized A beta 42 assemblies are inefficiently taken up into mammalian cells and have low toxicity in cell-based assays. Overall, these mechanistic studies support a pathological role of stable, beta-sheet-rich A beta 42 fibrils in AD, while structures with low beta-sheet content may be less relevant. (C) 2020 The Authors. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available